Home >   Products   >  Advanced Search

(CAS RN:5104-49-4 Product Number:F0371)


Synonym 2-(2-Fluorobiphenyl-4-yl)propionic Acid

General Information

Product Number F0371

* Items available from stock in Japan will be delivered in 10 business days.
* Please contact us if you need further information.
(Sales Dept Tel: +32 (0)3 735 07 00 E-mail: Sales-EU@TCIchemicals.com)
* To send your quote request for bulk quantities, please click on the “Request Bulk Quotation” button. Please note that for some of our products we cannot offer bulk quantities.
* TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.

Purity/Analysis Method >98.0%(T)(HPLC)
Storage Temperature
M.F. / M.W. C15H13FO2=244.27
CAS RN 5104-49-4
Related CAS RN
MDL Number MFCD00079303
Packaging and Container
  • Product Details
  • Safety & Regulations


Purity(HPLC) min. 98.0 area%
Purity(Neutralization titration) min. 98.0 %
Melting point 113.0 to 116.0 deg-C
Solubility in Methanol almost transparency


Reaxys-RN 2054451
PubChem SID 87570142
Merck Index(14) 4199
RTECS# DU8341000
EC Number 225-827-6


Signal Word Danger
Hazard Statements
  • H301
  • :Toxic if swallowed.
  • H315
  • :Causes skin irritation.
  • H319
  • :Causes serious eye irritation.
Precautionary Statements
  • P264
  • :Wash hands and face thoroughly after handling.
  • P270
  • :Do not eat, drink or smoke when using this product.
  • P280
  • :Wear protective gloves, eye protection.
  • P301+P310+P330
  • :IF SWALLOWED: Immediately call a POISON CENTER or doctor. Rinse mouth.
  • P302+P352+P332+P313+P362+P364
  • :IF ON SKIN: Wash with plenty of water. If skin irritation occurs: Get medical advice or attention. Take off contaminated clothing and wash it before reuse.
  • P305+P351+P338+P337+P313
  • :IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice or attention.

Transport Information

UN Number 2811
Class 6.1
Packing Group III
HS Number 2916399090


Flurbiprofen: A Racemic Non-Selective and Non-Steroidal Anti-Inflammatory Drug (NSAID)

Flurbiprofen is a racemic non-selective and non-steroidal anti-inflammatory drug (NSAID) of the 2-arylpropionic acid (2-APA) class, such as ibuprofen [I0415], (S)-ibuprofen [I0549], (±)-naproxen [M1220] and (S)-naproxen[M1021]. Only (S)-flurbiprofen [CAS: 51543-39-6] inhibited prostaglandin biosynthesis in vitro. Therefore, (S)-flurbiprofen has been shown to have both antiinflammatory and antinociceptive effects, whereas (R)-flurbiprofen [CAS: 51543-40-9] is antinociceptive but not antiinflammatory. In 2000s, some studies have shown that (R)-flurbiprofen is a potent reducer of levels of β-amyloid (Aβ). Hence, (R)-flurbiprofen had been under development for the treatment of Alzheimer's disease; however this development was discontinued in 2008. (The product is for research purpose only.)


Binding of Flurbiprofen to Human Serum Albumin

Flurbiprofen is known to have affinity for Human Serum Albumin (HSA) and to bind (interact) to drug binding site II on HSA. Those were confirmed using our ibuprofen with Surface Plasmon Resonance (SPR) and a method using fluorescent probes.

【SPR】Dose responses of flurbiprofen to HSA were confirmed by SPR. Biacore, as a SPR biosensor, was used for the assay, according to the user’s guide of the instrument.

<Assay condition> Sensor Chip: Series S Sensor Chip CM5, Immobilization: HAS (Amine Coupling method), Buffer : 5%DMSO in PBS.
<Result> “Square wave” sensorgrams were exhibited at each concentration, and concentration dependent binding of flurbiprofen to HSA was confirmed.

【Method using fluorescent probes】The drug biding site of flurbiprofen was confirmed using fluorescent probes which bind to drug binding site on HSA. Dansylamide (DNSA) [D5405] was used as fluorescent probe for site I, and dansylglycine (DNSG) [D5406], BD140 [D4898] were used as fluorescent probes for site II, and then bindings to site I and site II were confirmed.

<Assay condition> Buffer: 1 % DMSO in phosphate buffer (pH 7.2 - 7.5); HSA: 5 μM (DNSA), 20 μM (DNSG, BD140) (50 μL/well) (Fatty acid free HSA is recommended.); Flurbiprofen: each concentration (50 μL/well); DNSA: 80 μM, DNSG: 20 μM, BD140: 20 μM (50 μL/well); Incubation: 20-25 °C for 30 min; Measurement: plate-reader with excitation = 365 nm and emission = 480 nm (DNSA, DNSG), with excitation = 365 nm and emission = 585 nm (BD140).
<Result> As shown in upper diagram, inhibition against binding of dansylglycine and BD140 which are fluorescent probes for site II by flurbiprofen was confirmed. And also, little or extremely weak inhibition against binding of dansylamide which is fluorescent probe for site I was confirmed.

In these ways, our flurbiprofen can be used for study of interaction with HSA. Also, DNSA [D5405], DNSG [D5406] and BD140 [D4898] can be used for study of drug binding site on HSA.


PubMed Literature

Page Top